Pfizer Completes Acquisition Of Icagen
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) has completed its acquisition of Icagen, Inc., through the merger of its wholly owned subsidiary, Eclipse Acquisition Corp., with and into Icagen. Icagen is now a wholly-owned subsidiary of Pfizer.
Shire continued strong product sales performance in Q3
- Details
- Category: Shire
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces results for the three months to September 30, 2011.
After a good third quarter: Bayer confirms Group outlook
- Details
- Category: Bayer
Sales of the Bayer Group rose by 1.0 percent in the third quarter to EUR 8,670 million (Q3 2010: EUR 8,581 million). The currency- and portfolio-adjusted (Fx & portfolio adj.) increase was 4.8 percent.
Bristol-Myers Squibb Delivers Strong Third Quarter
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) has announced double-digit net sales growth in a quarter highlighted by important new data on ELIQUIS ® for stroke prevention in patients with atrial fibrillation and continued investment in external innovation with several strategic transactions.
AstraZeneca Third Quarter Results
- Details
- Category: AstraZeneca
AstraZeneca's Revenue in the third quarter was down 2 percent at CER, but was up 4 percent on an actual basis as a result of the positive impact of exchange rate movements. Revenue performance was impacted by government price interventions and the loss of more than $350 million in revenue to generic competition.
Amgen's Third Quarter Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) reported total revenue increased 3 percent during the third quarter of 2011 to $3,944 million versus $3,816 million in the third quarter of 2010. Total product sales increased 3 percent in the third quarter of 2011 to $3,877 million versus $3,759 million in the third quarter of 2010.
GSK delivers strong Q3 performance with underlying sales growth
- Details
- Category: GlaxoSmithKline
The breadth and mix of GSK's product and geographic portfolio is helping the Group to mitigate economic volatility. In the quarter, underlying and reported sales grew 6% and 3% respectively, reflecting growth across all three areas of our business - Pharmaceuticals, Vaccines and Consumer Healthcare.
More Pharma News ...
- Merck Total Revenues Increase by 4% to € 2.5 Billion
- Novartis achieves strong third quarter financial performance and pipeline progress
- Sanofi Appoints David Meeker Chief Executive Officer of Genzyme
- AIN457 provided rapid and significant relief of symptoms in up to 81% of patients with psoriasis
- Lilly Reports Third-Quarter 2011 Results
- Abbott Reports Strong Ongoing Third Quarter Results
- Bristol-Myers Squibb Announces Changes in Senior Management Team